|
1
|
Blander G and Guarente L: The Sir2 family
of protein deacetylases. Annu Rev Biochem. 73:417–435. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Imai S, Armstrong CM, Kaeberlein M and
Guarente L: Transcriptional silencing and longevity protein Sir2 is
an NAD-dependent histone deacetylase. Nature. 403:795–800. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Voelter-Mahlknecht S and Mahlknecht U:
Cloning, chromosomal characterization and mapping of the
NAD-dependent histone deacetylases gene sirtuin 1. Int J Mol Med.
17:59–67. 2006.PubMed/NCBI
|
|
4
|
Brunet A, Sweeney LB, Sturgill JF, Chua
KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu
LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW and
Greenberg ME: Stress-dependent regulation of FOXO transcription
factors by the SIRT1 deacetylase. Science. 303:2011–2015. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cohen HY, Lavu S, Bitterman KJ, Hekking B,
Imahiyerobo TA, Miller C, Frye R, Ploegh H, Kessler BM and Sinclair
DA: Acetylation of the C terminus of Ku70 by CBP and PCAF controls
Bax-mediated apoptosis. Mol Cell. 13:627–638. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Luo J, Nikolaev AY, Imai S, Chen D, Su F,
Shiloh A, Guarente L and Gu W: Negative control of p53 by Sir2alpha
promotes cell survival under stress. Cell. 107:137–148. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vaziri H, Dessain SK, Ng Eaton E, Imai SI,
Frye RA, Pandita TK, Guarente L and Weinberg RA: hSIR2(SIRT1)
functions as an NAD-dependent p53 deacetylase. Cell. 107:149–159.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hida Y, Kubo Y, Murao K and Arase S:
Strong expression of a longevity-related protein, SIRT1, in Bowen's
disease. Arch Dermatol Res. 299:103–106. 2007.PubMed/NCBI
|
|
9
|
Huffman DM, Grizzle WE, Bamman MM, Kim JS,
Eltoum IA, Elgavish A and Nagy TR: SIRT1 is significantly elevated
in mouse and human prostate cancer. Cancer Res. 67:6612–6618. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kuzmichev A, Margueron R, Vaquero A,
Preissner TS, Scher M, Kirmizis A, Ouyang X, Brockdorff N,
Abate-Shen C, Farnham P and Reinberg D: Composition and histone
substrates of polycomb repressive group complexes change during
cellular differentiation. Proc Natl Acad Sci USA. 102:1859–1864.
2005. View Article : Google Scholar
|
|
11
|
Jang KY, Kim KS, Hwang SH, Kwon KS, Kim
KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG and Moon WS:
Expression and prognostic significance prognostic of SIRT1 in
ovarian epithelial tumours. Pathology. 41:366–371. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen HC, Jeng YM, Yuan RH, Hsu HC and Chen
YL: SIRT1 promotes tumorigenesis and resistance to chemotherapy in
hepatocellular carcinoma and its expression predicts poor
prognosis. Ann Surg Oncol. 19:2011–2019. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen WY, Wang DH, Yen RC, Luo J, Gu W and
Baylin SB: Tumor suppressor HIC1 directly regulates SIRT1 to
modulate p53-dependent DNA-damage responses. Cell. 123:437–448.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baylin SB and Ohm JE: Epigenetic gene
silencing in cancer - a mechanism for early oncogenic pathway
addiction? Nat Rev Cancer. 6:107–116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lim CS: Human SIRT1: a potential biomarker
for tumorigenesis? Cell Biol Int. 31:636–637. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Japan Society of Gynecologic Oncology
(eds), . Formulation Committee of the Treatment Guidelines for
Cervical Cancer. Kanehara & Co.; Tokyo: 2011, (In
Japanese).
|
|
17
|
National Comprehensive Cancer Network, .
NCCN Clinical Practice Guidelines in Oncology - Cervical Cancer -
Version II. 2013
|
|
18
|
Morris M, Eifel PJ, Lu J, Grigsby PW,
Levenback C, Stevens RE, Rotman M, Gershenson DM and Mutch DG:
Pelvic radiation with concurrent chemotherapy compared with pelvic
and para-aortic radiation for high-risk cervical cancer. N Engl J
Med. 340:1137–1143. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Eifel PJ, Winter K, Morris M, Levenback C,
Grigsby PW, Cooper J, Rotman M, Gershenson D and Mutch DG: Pelvic
irradiation with concurrent chemotherapy versus pelvic and
para-aortic irradiation for high-risk cervical cancer: an update of
radiation therapy oncology group trial (RTOG) 90–01. J Clin Oncol.
22:872–880. 2004.PubMed/NCBI
|
|
20
|
Ishiko O, Sumi T, Yasui T, Matsumoto Y,
Kawamura N, Ogita S, Kamino T, Nakamura K and Yamada R:
Balloon-occluded arterial infusion chemotherapy, simple total
hysterectomy, and radiotherapy as a useful combination-therapy for
advanced cancer of the uterine cervix. Oncol Rep. 7:141–144.
2000.
|
|
21
|
Souhami L, Gil RA, Allan SE, Canary PC,
Araújo CM, Pinto LH and Silveira TR: A randomized trial of
chemotherapy followed by pelvic radiation therapy in stage IIIB
carcinoma of the cervix. J Clin Oncol. 9:970–977. 1991.PubMed/NCBI
|
|
22
|
Tattersall MH, Lorvidhaya V, Vootiprux V,
Cheirsilpa A, Wong F, Azhar T, Lee HP, Kang SB, Manalo A and Yen
MS: Randomized trial of epirubicin and cisplatin chemotherapy
followed by pelvic radiation in locally advanced cervical cancer.
Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology
Association. J Clin Oncol. 13:444–451. 1995.
|
|
23
|
Ishiko O, Sumi T, Yasui T, Matsumoto Y,
Ogita S, Kaminou T, Nakamura K and Yamada R: Tumor marker and MR
imaging criteria for evaluating the efficacy of cyclic
balloon-occluded arterial infusion for advanced cancer of the
uterine cervix. Oncol Rep. 7:827–830. 2000.PubMed/NCBI
|
|
24
|
Ishiko O, Sumi T, Yoshida H, Ogita S and
Yamada R: Expression of apoptosis regulatory proteins in advanced
cancer of the uterine cervix after cyclic balloon-occluded arterial
infusion chemotherapy. Int J Oncol. 18:1151–1155. 2001.
|
|
25
|
Okamoto E, Sumi T, Misugi F, Nobeyama H,
Hattori K, Yoshida H, Matsumoto Y, Yasui T, Honda K and Ishiko O:
Expression of apoptosis-related proteins in advanced uterine
cervical cancer after balloon-occluded arterial infusion
chemotherapy as an indicator of the efficiency of this therapy. Int
J Mol Med. 15:41–47. 2005.
|
|
26
|
Nobeyama H, Sumi T, Misugi F, Okamoto E,
Hattori K, Matsumoto Y, Yasui T, Honda K, Iwai K and Ishiko O:
Association of HPV infection with prognosis after neoadjuvant
chemotherapy in advanced uterine cervical cancer. Int J Mol Med.
14:101–105. 2004.PubMed/NCBI
|
|
27
|
Benedetti Panici P, Bellati F, Manci N,
Pernice M, Plotti F, Di Donato V, Calcagno M, Zullo MA, Muzii L and
Angioli R: Neoadjuvant chemotherapy followed by radical surgery in
patients affected by FIGO stage IVA cervical cancer. Ann Surg
Oncol. 14:2643–2648. 2007.
|
|
28
|
Tsuji K, Yamada R, Kawabata M, Mitsuzane
K, Sato M, Iwahashi M, Kitayama S and Nakano R: Effect of balloon
occluded arterial infusion of anticancer drugs on the prognosis of
cervical cancer treated with radiation therapy. Int J Radiat Oncol
Biol Phys. 32:1337–1345. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sironi S, Belloni C, Taccagni G and
DelMaschio A: Invasive cervical carcinoma: MR imaging after
preoperative chemotherapy. Radiology. 180:719–722. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim KH, Lee BH, Do YS, Chin SY, Park SY,
Kim BG and Jang JJ: Stage IIb cervical carcinoma: MR evaluation of
effect of intraarterial chemotherapy. Radiology. 192:61–65. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sinicrope FA, Ruan SB, Cleary KR, Stephens
LC, Lee JJ and Levin B: bcl-2 and p53 oncoprotein expression during
colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
|
|
32
|
Firestein R, Blander G, Michan S,
Oberdoerffer P, Ogino S, Campbell J, Bhimavarapu A, Luikenhuis S,
de Cabo R, Fuchs C, Hahn WC, Guarente LP and Sinclair DA: The SIRT1
deacetylase suppresses intestinal tumorigenesis and colon cancer
growth. PLoS One. 3:e20202008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang RH, Zheng Y, Kim HS, Xu X, Cao L,
Luhasen T, Lee MH, Xiao C, Vassilopoulos A, Chen W, Gardner K, Man
YG, Hung MC, Finkel T and Deng CX: Interplay among BRCA1, SIRT1,
and Survivin during BRCA1-associated tumorigenesis. Mol Cell.
32:11–20. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
zur Hausen H: Papillomaviruses causing
cancer: evasion from host-cell control in early events in
carcinogenesis. J Natl Cancer Inst. 92:690–698. 2000.PubMed/NCBI
|
|
35
|
Werness BA, Levine AJ and Howley PM:
Association of human papillomavirus types 16 and 18 E6 proteins
with p53. Science. 248:76–79. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bremer GL, Tieboschb AT, van der Putten
HW, de Haan J and Arends JW: p53 tumor suppressor gene protein
expression in cervical cancer: relationship to prognosis. Eur J
Obstet Gynecol Reprod Biol. 63:55–59. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Allison SJ, Jiang M and Milner J:
Oncogenic viral protein HPV E7 up-regulates the SIRT1 longevity
protein in human cervical cancer cells. Aging (Albany NY).
1:316–327. 2009.PubMed/NCBI
|
|
38
|
Morishita M, Sumi T, Nakano Y, Teramae M,
Fukuda T, Nobeyama H, Yoshida H, Matsumoto Y, Yasui T and Ishiko O:
Expression of mitotic-arrest deficiency 2 predicts the efficacy of
neoadjuvant chemotherapy for locally advanced uterine cervical
cancer. Exp Ther Med. 3:341–346. 2011.
|
